Public money, private software, and a web of overlapping professional ties. When a major technology supplier secures a massive government deal, people expect complete separation between the watchers and the watched. Right now, that line looks remarkably blurry inside Britain's healthcare system.
At least half a dozen senior figures within the health service have held financial or advisory ties to Palantir, the controversial US data analytics giant steering a massive £330mn NHS contract. While public declarations exist in official transparency registers, the sheer frequency of these connections forces a hard look at how public sector tech procurement actually works.
Following the Digital Trail
Let's look at the facts without getting bogged down in corporate spin. Palantir didn't arrive yesterday. They embedded themselves early in the pandemic, offering their Foundry software for a nominal fee to track personal protective equipment and vaccine rollouts. That £1 starting point eventually morphed into long-term infrastructure dominance, culminating in the Federated Data Platform agreement.
As that software footprint expanded, personal links grew right alongside it. Public records show a pattern of advisory roles, shareholdings, and professional relationships spanning key digital leadership positions.
- Tim Peachey served on Palantir's UK health advisory board while simultaneously acting as deputy chair of the Isle of Wight NHS Trust.
- Alex Crossley, director of transformation strategy, finance, and delivery for NHS England, previously held Palantir shares before selling them.
- Peter Thomas, an executive at Moorfields Eye Hospital, disclosed historical shareholdings in the tech firm.
- William Monaghan, a chief digital information officer across multiple hospital groups, also reported past holdings.
Transparency rules were technically followed. Every single one of these connections made it onto official registers of interest. But transparency is not the same thing as immunity to conflict. When leaders shaping national tech strategies own stock in the exact vendor building the plumbing, public trust takes a hit.
The Compliance Argument Versus Reality
NHS England defends these disclosures fiercely. The official line points out that declaring an interest is what you are supposed to do, and that these individuals had no direct hand in awarding the major platform contract. Palantir itself notes that purchasing stock in a publicly traded tech giant is standard behavior, comparing it to holding shares in Microsoft or other industry heavyweights.
Technically, they are correct. Owning shares in a massive public company doesn't automatically mean a conspiracy is afoot.
Yet, optics matter in public health. The health service runs on public faith. When a private contractor builds a centralized data system to pool patient information across the country, any whiff of a cozy relationship between regulators, executives, and suppliers creates an immediate PR crisis. People worry about data privacy, commercial creep, and whether public assets are being managed with absolute detachment.
What Needs to Change
Fixing this isn't about banning health service workers from ever owning shares or cutting off all private sector collaboration. Technology moves too fast for public institutions to build everything from scratch. They need commercial partners.
What needs an overhaul is the threshold for acceptability at the top tier of leadership. If you are steering national transformation strategies, you shouldn't hold financial interests in the vendors bidding for your business, period. Disclosure is a safety net for auditors, not a free pass for potential conflicts.
Until leadership rules tighten up, every new tech rollout will face an uphill battle against public skepticism. The burden of proof rests entirely on the institution to prove that closeness to Silicon Valley doesn't override the health needs of everyday patients.
